{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Colorectal Cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2691909"],"location":["China"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase II clinical study of advanced PMMR colorectal cancer treated by cindilimab and regofinib combinating radiotherapy and Stereotactic therapy","description":"Interventions: Case series:Sintilimab and Regorafenib plus Stereotactic Radiotherapy\nPrimary outcome(s): Overall survival, OS\nStudy Design: Single arm","dates":{"creation":"2020-05-15"},"accession":"2691909","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000031237"]}}